Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Uniphar PLC ( (GB:UPR) ) has provided an announcement.
Uniphar PLC reported a strong financial performance for the first half of 2025, achieving double-digit adjusted EPS growth and approximately 8% organic gross profit growth. The company completed a €35m share buyback program and maintained a solid liquidity position with a Net Bank Debt/EBITDA of 1.9x. Looking ahead, Uniphar remains optimistic about its growth prospects, driven by declining interest rates and a robust pipeline of acquisition opportunities, aiming to reach a €200m EBITDA target by 2028 with significant organic growth.
More about Uniphar PLC
Uniphar PLC is an international diversified healthcare services business. The company operates in the healthcare industry, focusing on providing services across three main divisions: Pharma, Medtech, and Supply Chain & Retail. Uniphar is committed to growth through both organic means and strategic acquisitions, maintaining a strong market position with a disciplined approach to capital allocation.
Learn more about UPR stock on TipRanks’ Stock Analysis page.